Loading…
Reported covered position: Professional Staff, Committee on Aging
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Drug Price Transparency in Medicaid Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Source: Senate LDA
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Medicaid VBPs for Patients Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Pharmacy Benefits Manager Accountability Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Transparent PRICE Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Protecting Patients Against PBM Abuses Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Protecting Patients Against PBM Abuses Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Drug Shortage Prevention Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Transparent PRICE Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Promoting Transparency and Healthy Competition in Medicare Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes.
Promoting Transparency and Healthy Competition in Medicare Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Providers and Payers COMPETE Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Providers and Payers COMPETE Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes.
Providers and Payers COMPETE Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Fairness for Patient Medications Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
340B Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
PATIENT Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Ensuring Access to Lifesaving Drugs Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Drug Origin Transparency Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Transparency in Coverage Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Hidden Fee Disclosure Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Health DATA Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Health Care Price Transparency Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Lowering Drug Costs for American Families Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Share the Savings with Seniors Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Lower Costs, More Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Medicare PBM Accountability Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Prescription Pricing for the People Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Pharmacy Benefit Manager Transparency Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Pharmacy Benefit Manager Reform Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
PBM Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
PBM Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes.
PBM Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Protect Patient Access to Pharmacies Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Ensuring Access to Lower-Cost Medicines for Seniors Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Medicare PBM Accountability Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Strengthening Pharmacy Access for Seniors Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
NO PBMs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
Modernizing and Ensuring PBM Accountability Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691 Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act. S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; PBM Oversight Act of 2023; Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclosure Act; H.R.3285 - Fairness for Patient Medications Act; S.2973, Modernizing and Ensuring PBM Accountability Act. H.R.3285 - Fairness for Patient Medications Act; H.R. ___, the Stop Drug Shortages Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Addressing Social Determinants in Medicare Advantage Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Restoring Hope for Mental Health and Well-Being Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Mental Health Matters Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Prescription Pricing for the People Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
CONNECT for Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Pharmacy DIR Reform To Reduce Senior Drug Costs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Improving Seniors’ Timely Access to Care Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Telehealth Extension and Evaluation Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Telehealth Extension and Evaluation Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Affordable Insulin Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Affordable Insulin Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
Pharmacy Benefit Manager Transparency Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Improving Health Insurance Affordability Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to S.263, the Worker Health Coverage Protection Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
American Rescue Plan Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Telehealth Modernization Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Lower Costs, More Cures Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Lower Costs, More Cures Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Elijah E. Cummings Lower Drug Costs Now Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Infrastructure Investment and Jobs Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to S.263, the Worker Health Coverage Protection Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Improving Social Determinants of Health Act of 2021
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Inflation Reduction Act of 2022
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes. Issues related to pharmaceutical affordability and access in Medicare under H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act. H.R. 4881, and issues related to point-of-sale rebates in Part D Low-Income Subsidy under the Medicare program. S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications. S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D. H.R. 3282, Promoting Transparency and Healthy Competition in Medicare Act. H.R. 3284, Providers and Payers COMPETE Act, To require the Secretary of Health and Human Services to consider, within the annual rulemaking process, the effect of regulatory changes to certain Medicare payment systems on provider and payer consolidation, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
* Issues related to the Improving Seniors Timely Access to Care Act of 2021. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies; Medicare Program; Contract Year (CY) 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* H.R. 6833/S. 3700, the Affordable Insulin Now Act and related issues. * Issues related to FY 2023 Appropriations, including telehealth, mental health, and health care affordability. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act of 2022. * Issues related to H.R. 7780, the Mental Health Matters Act. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to S. 1388, the Prescription Pricing for the People Act of 2021. * Issues related to S. 4293, the Pharmacy Benefit Manager Transparency Act of 2022. * P.L. 117-103, the Consolidated Appropriations Act, 2022. * P.L.117-169, the Inflation Reduction Act of 2022, including Enhanced advance premium tax credits (APTCs) and Medicare Part D redesign.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act. * Issues related to the Centers for Medicare & Medicaid Services Maryland Total Cost of Care Model.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
* P.L. 117-103, the Consolidated Appropriations Act, 2022. * Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * H.R. 6833/S. 3700, the Affordable Insulin Now Act.
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to mental health parity in H.R. 5376 Build Back Better Act. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 117-58, the Infrastructure Investment and Jobs Act * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the S. 499, the Improving Health Insurance Affordability Act of 2021 * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to H.R.3684, the Infrastructure Investment and Jobs Act * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the H.R. 5376 Build Back Better Act, budget reconciliation legislation. * Issues related to the Improving Health Care Affordability Act. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues related to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay.
* Issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021 * Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to S.909, The Prescription Drug Price Relief Act; S. 908, The Medicare Drug Price Negotiation Act; and S. 920, The Affordable and Safe Prescription Drug Importation Act. * Issues related to telehealth, including H.R. 1332/S. 368, the Telehealth Modernization Act and S. 1512, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * Issues retated to H.R. 19/S. 2164, the Lower Costs, More Cures Act. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
* Issues related to P.L. 117-2 (H.R. 1319), the American Rescue Plan Act of 2021. * Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act; P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); Issues related to P.L. No: 116-260, the Consolidated Appropriations Act, 2021. * Issues related to S.263, the Worker Health Coverage Protection Act. * Issues related to H.R. 379/S. 104 - Improving Social Determinants of Health Act of 2021. * Issues related to the administration of the 340B drug pricing program * Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. * Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. * July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. * June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First".
-Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Policies that impact public programs payments for high cost drugs including gene therapies. -H.R.7659/S. 4840, Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, to amend title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes. -Issues related to prior authorization and utilization management, H.R. 3107, the Improving Seniors' Timely Access to Care Act of 2019. -Issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800 / H.R. 925 the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act) -Issues related to H.R. 6810, the Health Care Protection Act, and H.R. 6514, the Worker Health Coverage Protection Act, and S. 4329, the Continuous Health Coverage for Workers Act. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. -H.R. 6561/S. 4440 - Improving Social Determinants of Health Act of 2020. -Healthcare, Economic Assistance, Liability, And Schools (HEALS Act), including S. 4317 the Safe to Work Act; S. 4318, the American Workers, Families, And Employers Assistance Act; S. 4321, the Continuing Small Business Recovery And Paycheck Protection Program Act; S. 4322, the Safely Back To School And Back To Work Act; and S. 4323, Time to Rescue United States Trusts Act of 2020 (TRUST Act). -Issues related to H.R. 7839 Continuing Access to In Home Intravenous Immunoglobulin (IVIG) Act. -Issues related to H.R. 8308, to amend the Public Health Service Act to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person, and for other purposes.
-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act) -Issues related to H.R. 6810, the Health Care Protection Act, H.R. 6379, the Take Responsibility for Workers and Families Act, and H.R. 6514, the Worker Health Coverage Protection Act -P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -S 1323, UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients.
-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.
-Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136., Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. - Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. - Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019; H.R. 3630, The No Surprises Act; and H.R. 5800, The Ban Surprise Billing Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients.
-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients.
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019.
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act.
-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, and non-discrimination provisions. -21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability. -Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation. -Issues related to H.R. 861, the End Surprise Billing Act.
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Issues related to the proposed rule: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. -Draft Patient Affordability, Value and Efficiency Act, legislation to facilitate new pharmacy payment models. -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Issues related to the opioid epidemic, including H.R. 6, SUPPORT for Patients and Communities Act and and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to implementation of provisions in the Bipartisan Budget Act of 2018 that require increased integration of Medicare and Medicaid benefits by Dual-Eligible Special Needs Plans (D-SNPs) beginning in 2021.
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, the Employer Relief Act of 2018, regarding a one-year delay of the Cadillac Tax. H.R. 4620, the the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 6, the SUPPORT for Patients and Communities Act and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.
Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to the proposed rule: Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Issues related to the opioid epidemic, including H.R. 6, SUPPORT for Patients and Communities Act and and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to implementation of provisions in the Bipartisan Budget Act of 2018 that require increased integration of Medicare and Medicaid benefits by Dual-Eligible Special Needs Plans (D-SNPs) beginning in 2021. Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P).
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017 and the Better Care Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Senate motion to concur in the House amendment to the Senate amendment to H.R.195, CR/CHIP, with further amendment (includes: CR funding until February 8, 2018; 6 year CHIP; ACA tax delays).
Issues related to regulations on claims procedure for plans providing disability benefits. Issues related to the proposed Cigna-Express Scripts transaction.
Issues related to anti-trust and the proposed Cigna-Express Scripts transaction. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Issues related to the opioid epidemic, including H.R. 6, SUPPORT for Patients and Communities Act and and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to implementation of provisions in the Bipartisan Budget Act of 2018 that require increased integration of Medicare and Medicaid benefits by Dual-Eligible Special Needs Plans (D-SNPs) beginning in 2021.
Issues related to the drug pricing RFI.
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017 H.R.5963, regarding relief from the Health Insurance Tax. Issues related to the implementation of international tax provisions under P.L. 115-97, the Tax Cuts and Jobs Act.
Issues related to regulations on claims procedure for plans providing disability benefits. Issues related to the proposed Cigna-Express Scripts transaction.
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically the Overdose Prevention and Patient Safety Act (OPPS Act). Issues related to H.R.1625, the Consolidated Appropriations Act of 2018.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program.
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Issues relating to P.L. 114-10, the Medicare Access and CHIP Reauthorization Act, including alternative payment models. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 3545 and Protecting Jessica Grubbs Legacy Act (Legacy Act), S. 1850.
Issues related to regulations on claims procedure for plans providing disability benefits.
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017 and the Better Care Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. H. Con. Res. 71, the FY2018 Budget Resolution and issues related to corporate tax reform.
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017 and the Better Care Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program; 2018 Medicare Advantage Advance Notice Draft Call Letter, including Star Ratings and Encounter Data.
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. Issues relating to P.L. 114-10, the Medicare Access and CHIP Reauthorization Act, including alternative payment models.
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017.
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017.
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. Issues relating to P.L. 114-10, the Medicare Access and CHIP Reauthorization Act, including alternative payment models.
Issues related to antitrust and the proposed Cigna-Anthem transaction.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. Issues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to H.R. 2 - The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 5659 - Expanding Seniors Receiving Dialysis Choice Act of 2016.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act). In addition, issues relating to the 40% excise tax. Issues relating to Health Savings Accounts: H.R. 4469 the Health Savings Act of 2016, S.2499, the Health Savings Act of 2016, H.R. 4832, the Health Savings Protection Act.
Issues relating to mental health and general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015. Issues related to S. 1945, the Mental Health Reform Act of 2015, S. 524 the Comprehensive Addiction and Recovery Act of 2016, and S. 2680, the Mental Health Reform Act of 2016; H.R. 5046 the Comprehensive Opioid Abuse Reduction Act and H.R. 2646 the Helping Family in Mental Crisis Act of 2016. Issues relating to employer sponsored healthcare.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. Issues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to Medigap insurance, and H.R. 2, The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 2579 - Securing Care for Seniors Act of 2015. Issues related to the introduction of S. 2104, A bill to amend title XVIII of the Social Security Act to provide relief to Medicare Advantage plans with a significant number of dually eligible or low-income subsidy beneficiaries and to prevent the termination of two star plans.
Issues relating to mental health and general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015. Issues related to S. 1945, the Mental Health Reform Act of 2015, S. 524 the Comprehensive Addiction and Recovery Act of 2016, and S. 2680, the Mental Health Reform Act of 2016; H.R. 5046 the Comprehensive Opioid Abuse Reduction Act and H.R. 2646 the Helping Family in Mental Crisis Act of 2016. Issues relating to employer sponsored healthcare.
Issues related to antitrust and the proposed Cigna-Anthem transaction.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act). In addition, issues relating to the 40% excise tax. Issues relating to Health Savings Accounts: H.R. 4469 the Health Savings Act of 2016, S.2499, the Health Savings Act of 2016, H.R. 4832, the Health Savings Protection Act.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act) and S. 183, the Jobs and Premium Protection Act. In addition, H.R. 879, H.R. 2050, S. 2045 and S. 2075, relating to the 40% excise tax, and H.R. 3462 and S. 775, the Self Insurance Protection Act. Issues relating to S. 183 and H.R.928, to repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act. Issues related to international taxes and reform.
Improve prescription drug access: H.R. 1600: Patients Access to Treatments Act of 2015; provisions related to improving prescription drug access. Issues related to the high cost of specialty drugs; H.R. 793, Ensuring Seniors Access to Local Pharmacies Act; H.R. 244. MAC Transparency Act.
Issues related to employer financing of private disability insurance.
Issues relating to general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Also, issues related to H.R. 928 and S. 183, Jobs and Premium Protection Act; and medicare supplemental insurance. In addition, in support of implementation of expatriate provisions in H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015. Issues relating to the introduction of H.R. 1624 - Protecting Affordable Coverage for Employees Act, H.R. 3462, and S. 775, the Self Insurance Protection Act. . Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015.
Improve prescription drug access: H.R. 1600: Patients Access to Treatments Act of 2015; provisions related to improving prescription drug access. Issues related to the high cost of specialty drugs; H.R. 793, Ensuring Seniors Access to Local Pharmacies Act; H.R. 244. MAC Transparency Act.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act) and S. 183, the Jobs and Premium Protection Act. In addition, H.R. 879 and H.R. 2050, relating to the 40% excise tax, and H.R. 3462 and S. 775, the Self Insurance Protection Act. Issues relating to S. 183 and H.R.928, to repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act) and H.R. 763; To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act and S. 603; Jobs and Premium Protection Act. In addition, H.R. 4414, The Expatriate Health Coverage Clarification Act, H.R 3367, The Small Business and Family Relief Act, and H.R. 3462 and S. 1735, about Self Insurance. Issues related to the new Taiwan financial services tax and its impact on foreign insurers.
Issues relating to general health and health care legislation and regulation - Including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010); H.R. 763 and S. 603, Jobs and Premium Protection Act; H.R. 3367, The Small Business and Family Relief Act; and medicare supplemental insurance. In addition, in support of H.R. 4414, The Expatriate Health Coverage Clarification Act and expatriate provisions in HR 83, Consolidated and Further Continuing Appropriations Act, 2015.
Improve prescription drug access: H.R. 460: Patients Access to Treatments Act of 2013, S867. Medicare Prescription Drug Program Integrity and Transparency Act of 2013; provisions related to improving prescription drug access. Issues related to the high cost of specialty drugs; H.R. 4577 about pharmacy access and quality
Ongoing implementation of payment and regulatory issues for the Medicare Advantage and Medicare Part D prescription drug programs, and of various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage and Medicare Part D prescription drug programs, and of various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act) . HR 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013.
Issues related to employer financing of private disability insurance. Issues related to the new Taiwan financial services tax and its impact on foreign insurers.
* Issues related to the Advance Notice of Methodological Changes for Calendar Year (CY) 2023 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. * H.R. 3554/S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act. * H.R. 4074, To expand the availability of supplemental benefits to certain Medicare Advantage enrollees. * H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021. * H.R. 5376, Issues related to Medicaid coverage in the Build Back Better Act. * Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule. * Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. * S. 3593, Telehealth Extension and Evaluation Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
-Issues related to H.R. 6644 / S. 3741, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency -Issues related to H.R. 6800 / H.R. 925 the Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act). -Issues related to H.R. 6810, the Health Care Protection Act, and H.R. 6514, the Worker Health Coverage Protection Act, and S. 4329, the Continuous Health Coverage for Workers Act. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act, and H.R. 5800, The Ban Surprise Billing Act. -Issues related to P.L. 116-123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, Families First Coronavirus Response Act. P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act). HR 6379, Take Responsibility for Workers and Families Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -Issues related to the drug and medical device supply chain concerns related to the coronavirus response efforts. -Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans, and non-discrimination provisions. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First" -July 24, 2020 Executive Orders that direct federal agencies to prioritize policies that would: (1) permit drug importation from Canada and other countries, and specifically authorizes the re-importation of insulin products; (2) ensure that prices charged to low-income uninsured patients for insulin and epinephrine at Federally Qualified Health Centers (FQHCs are federally subsidized clinics that commonly participate in the 340B drug pricing program) align with the costs at which the FQHC acquired the drugs; (3) ban drug rebates in Medicare that are not passed at the point of sale; and (4) advance a most favored nation (MFN) rule to lower Medicare drug payments to prices similar to what other countries pay. -Issues related to H.R. 6561/S. 4440 - Improving Social Determinants of Health Act of 2020 and H.R. 4004/ S. 2986, the Social Determinants Accelerator Act of 2019. -Issues related to H.R. 7839 Continuing Access to In Home Intravenous Immunoglobulin (IVIG) Act. -Issues related to H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act. -S.2543, The Prescription Drug Pricing Reduction Act of 2019. -H.R. 2296, the More Efficient Tools to Realize Information For Consumers (METRIC) Act.
-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.
-Design, coverage and affordability of pharmacy benefits in Exchanges and the commercial market, including: e-Prescribing (eRx), Electronic Prescribing for Controlled Substances (EPCS), electronic prior authorization, step therapy, Pharmacy Benefit Manager (PBM) disclosure, medical loss ratio (MLR), and specialty pharmacy tiering. Implementation of biosimilars pathway from the Biologics Price Competition and Innovation Act (BPCIA). -Risk Evaluation and Mitigation Strategies (REMS) reform. H.R. 965/S. 340, the CREATES Act of 2019. -Drug patent settlements. H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019; S.64, the Preserve Access to Affordable Generics and Biosimilars Act. -H.R. 2279, Safe Step Act (Step Therapy Bill). -Pharmacy issues related to S. 1895, the Lower Health Care Costs Act. -Issues related to S. 1384, the Prescription Drug Rebate Reform Act of 2019. -Issues related to H.R. 3, the Lower Drug Costs Now Act of 2019. -H.R. 4946, Ensuring Seniors Access to Local Pharmacies Act of 2019. -H.R. 5281, Drug Price Transparency in Medicaid Act of 2019. -H.R. 5304, PBM Transparency in Prescription Drug Costs Act. -Issues related to drug shortages, and pharmaceutical procurement processes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Vice President of the U.S.
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act. -The Prescription Drug Pricing Reduction Act of 2019 (Chairman's Mark). -H.R. 2996, the More Efficient Tools to Realize Information For Consumers (METRIC) Act.
-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.
-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability. -Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation. -Issues related to H.R. 861, the End Surprise Billing Act; H.R. 3502, The Protecting People from Surprise Medical Bills Act; H.R.2328, Community Health Investment, Modernization, and Excellence Act of 2019 and H.R. 3630, The No Surprises Act. -Issues related to 42 C.F.R. Part 2, in H.R. 2062, The Overdose Prevention and Patient Safety Act and S. 1012, the the Protecting Jessica Grubbs Legacy Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets. -June 24, 2019 Executive Order, "Improving Price and Quality Transparency in American Healthcare to Put Patients First". -S.1323, the UNDERSTAND Act, legislation to improve the collection of social determinates of health (SDOH) data using ICD-10 Z-codes to track and report standardized definitions of SDOH affecting patients. -Issues related to utilization management and S.2546, The Safe Step Act of 2019, legislation to amend the Employee Retirement Income Security Act (ERISA) to require group health plans to streamline step therapy protocols and better ensure patients are able to access treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
-Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms and coverage expansion proposals, stand-alone dental plans and non-discrimination provisions. -21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability. -Implementation of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), as amended by the Affordable Care Act, the 21st Century Cures Act, and ERISA, including DOL proposed FAQs about Mental Health and Substance Use Disorder Parity Implementation. -Issues related to H.R. 861, the End Surprise Billing Act and "No Surprises Act" Discussion Draft. -Issues related to 42 C.F.R. Part 2, in H.R. 2062, The Overdose Prevention and Patient Safety Act and S. 1012, the the Protecting Jessica Grubbs Legacy Act. -Issues related to S. 1895, the Lower Health Care Costs Act, including: surprise billing, and transparency and information sharing in the individual and commercial markets.
-Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. -H.R. 748/S. 684, Middle Class Health Benefits Tax Repeal Act of 2019, legislation to repeal a 40% ACA excise tax on certain employer-sponsored health insurance plans. -S.172/H.R. 1398, the Health Insurance Tax (HIT) Relief Act of 2019, legislation to suspend the ACA's health insurance tax (HIT) in 2020 and 2021. S.80, Jobs and Premium Protection Act, full repeal of the HIT.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to the proposed rule: Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. H.R.5963, To delay the reimposition of the annual fee on health insurance providers until after 2020, regarding relief from the Health Insurance Tax. Issues related to the implementation of international tax provisions under P.L. 115-97, the Tax Cuts and Jobs Act.
Issues related to anti-trust and the proposed Cigna-Express Scripts transaction. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, the Employer Relief Act of 2018, regarding a one-year delay of the Cadillac Tax. H.R. 4620, the the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 6, the SUPPORT for Patients and Communities Act and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans. 21st Century Cures Act, section 4004, Reducing Regulatory and Administrative Burden Relating to the Use of Health IT and EHRs, information blocking and interoperability.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically the Overdose Prevention and Patient Safety Act (OPPS Act). Issues related to H.R.1625, the Consolidated Appropriations Act of 2018.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to the proposed rule: Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. H.R.5963, To delay the reimposition of the annual fee on health insurance providers until after 2020, regarding relief from the Health Insurance Tax. Issues related to the implementation of international tax provisions under P.L. 115-97, the Tax Cuts and Jobs Act.
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, the Employer Relief Act of 2018, regarding a one-year delay of the Cadillac Tax. H.R. 4620, the the Protecting Families and Small Businesses Act of 2017, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act), H.R. 6, the SUPPORT for Patients and Communities Act and S. 2680, the Opioid Crisis Response Act of 2018. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
Issues related to anti-trust and the proposed Cigna-Express Scripts transaction. Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Issues related to the opioid epidemic and introduced H.R. 6, SUPPORT for Patients and Communities Act.
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records, specifically H.R. 3545, H.R. 5795, and H.R.6082, the Overdose Prevention and Patient Safety Act (OPPS Act). Issues related to proposed changes to the definition of Employer Under Section 3(5) of ERISA for Association Health Plans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019
Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017 and the Better Care Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. Senate motion to concur in the House amendment to the Senate amendment to H.R.195, CR/CHIP, with further amendment (includes: CR funding until February 8, 2018; 6 year CHIP; ACA tax delays).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
Tax Cuts and Jobs Act (H.R. 1). Issues related to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017 and the Better Care Reconciliation Act. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017, and H.R. 4616, regarding a one-year delay of the Cadillac Tax. H.R. 4620, regarding relief from the Health Insurance Tax. H. Con. Res. 71, the FY2018 Budget Resolution and issues related to corporate tax reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. Issues relating to P.L. 114-10, the Medicare Access and CHIP Reauthorization Act, including alternative payment models. Substance use disorders and 42 CFR Part 2 - Confidentiality of Substance Use Disorder Patient Records.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program, 2018 Medicare Advantage Advance Notice Draft Call Letter, Star Ratings, and Encounter Data.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
Issues relating to P.L. 111-148, the Patient Protection and Affordable Care Act and P.L. 111-152, the Health Care and Education Reconciliation Act, and H.R. 1628, the American Health Care Act of 2017, the Better Care Reconciliation Act, including exchanges, cost sharing reduction, market reforms, and non-discrimination provisions. The high cost employer health insurance excise tax, including H.R. 173 and S. 58, the Middle Class Health Benefits Tax Repeal Act of 2017. Issues relating to P.L. 114-10, the Medicare Access and CHIP Reauthorization Act, including alternative payment models.
Issues related to regulations on claims procedure for plans providing disability benefits.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
Issues related to antitrust and the proposed Cigna-Anthem transaction. Issues related to regulations on claims procedure for plans providing disability benefits.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program; 2018 Medicare Advantage Advance Notice Draft Call Letter, including Star Ratings and Encounter Data.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
Issues related to antitrust and the proposed Cigna-Anthem transaction. Issues related to regulations on claims procedure for plans providing disability benefits.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program; 2018 Medicare Advantage Advance Notice Draft Call Letter, including Star Ratings and Encounter Data.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act). S. 3060, the Small Business Health Care Relief Act and issues relating to the 40% excise tax, including H.R. 4832, the Health Savings Protection Act.
Regulations related to Expatriate Health Coverage Clarification Act (EHCCA) of 2014 (P.L. 113-235) and the implementation of patient protection and affordable care act (PPACA).
Issues relating to mental health and general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). The health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015. S. 1945, the Mental Health Reform Act of 2015, S. 524 the Comprehensive Addiction and Recovery Act of 2016, and S. 2680, the Mental Health Reform Act of 2016; H.R. 5046 the Comprehensive Opioid Abuse Reduction Act and H.R. 2646 the Helping Family in Mental Crisis Act of 2016. Issues relating to employer sponsored healthcare.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Regulations related to Expatriate Health Coverage Clarification Act (EHCCA) of 2014 (P.L. 113-235). Health Insurance issues related to implementation of patient protection and affordable care act (PPACA).
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. Issues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to H.R. 2 - The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 2579 - Securing Care for Seniors Act of 2015. Issues relating to H.R. 5659 - Expanding Seniors Receiving Dialysis Choice Act of 2016.
Issues related to antitrust and the proposed Cigna-Anthem transaction.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Issues related to antitrust and the proposed Cigna-Anthem transaction.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act). In addition, issues relating to the 40% excise tax. Issues relating to Health Savings Accounts: H.R. 4469 the Health Savings Act of 2016, S.2499, the Health Savings Act of 2016, H.R. 4832, the Health Savings Protection Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Issues related to employer financing of private disability insurance.
Issues relating to mental health and general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015. Issues related to S. 1945, the Mental Health Reform Act of 2015, S. 524, the Comprehensive Addiction and Recovery Act of 2016, and S. 2680, the Mental Health Reform Act of 2016. Issues relating to employer sponsored healthcare.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. Issues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to Medigap insurance, and H.R. 2, The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 2579 - Securing Care for Seniors Act of 2015. Issues related to the introduction of S. 2104, A bill to amend title XVIII of the Social Security Act to provide relief to Medicare Advantage plans with a significant number of dually eligible or low-income subsidy beneficiaries and to prevent the termination of two star plans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to employer financing of private disability insurance.
Issues relating to general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Also, issues related to H.R. 928 and S. 183, Jobs and Premium Protection Act; and medicare supplemental insurance. In addition, in support of implementation of expatriate provisions in H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015. Issues relating to the introduction of H.R. 1624 - Protecting Affordable Coverage for Employees Act, H.R. 3462, and S. 775, the Self Insurance Protection Act. Issues related to the health insurance excise tax, including H.R. 2050 and H.R. 879, S. 2045, the Middle Class Health Benefits Repeal Act of 2015, and S. 2075, the American Worker Health Care Tax Relief Act of 2015.
Issues related to antitrust and the proposed Cigna-Anthem transaction.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program, including H.R. 2570 and H.R. 2582. Issues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to Medigap insurance, and H.R. 2, The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 1600, the Patient's Access to Treatments Act of 2015. Issues relating to H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act, and H.R. 2579 - Securing Care for Seniors Act of 2015. Issues related to the introduction of S. 2104, A bill to amend title XVIII of the Social Security Act to provide relief to Medicare Advantage plans with a significant number of dually eligible or low-income subsidy beneficiaries and to prevent the termination of two star plans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
Issues related to antitrust and the proposed Cigna-Anthem transaction.
Improve prescription drug access: H.R. 1600: Patients Access to Treatments Act of 2015; provisions related to improving prescription drug access. Issues related to the high cost of specialty drugs; H.R. 793, Ensuring Seniors Access to Local Pharmacies Act; H.R. 244. MAC Transparency Act.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act) and S. 183, the Jobs and Premium Protection Act. In addition, H.R. 879, H.R. 2050, S. 2045 and S. 2075, relating to the 40% excise tax, and H.R. 3462 and S. 775, the Self Insurance Protection Act. Issues relating to S. 183 and H.R.928, to repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act.
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program, including H.R. 2570 and H.R. 2582. Isues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to Medigap insurance, and H.R. 2, The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 1600, the Patient's Access to Treatments Act of 2015. Issues relating to the reintroduction of H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013, and H.R. 2753 - Securing Care for Seniors Act of 2013. Issues related to the instroduction of S. 2104A bill to amend title XVIII of the Social Security Act to provide relief to Medicare Advantage plans with a significant number of dually eligible or low-income subsidy beneficiaries and to prevent the termination of two star plans.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
Ongoing implementation of payment and regulatory issues for the Medicare Advantage program, including H.R. 2570 and H.R. 2582. Isues relating to the Medicare Part D prescription drug program, various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). Issues relating to Medigap insurance, and H.R. 2, The Medicare Access and CHIP Re authorization Act of 2015. Issues relating to H.R. 1600, the Patient's Access to Treatments Act of 2015. Issues relating to the reintroduction of H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013, and H.R. 2753 - Securing Care for Seniors Act of 2013.
Issues related to employer financing of private disability insurance.
Issues relating to general health and health care legislation and regulation, including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010). Also, issues related to H.R. 928 and S. 183, Jobs and Premium Protection Act; and medicare supplemental insurance. In addition, in support of implementation of expatriate provisions in H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015. Issues relating to the introduction of H.R. 1624 - Protecting Affordable Coverage for Employees Act, H.R. 3462 and S. 775, the Self Insurance Protection Act, and H.R. 2050 and H.R. 879, related to the health insurance excise tax.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
Ongoing implementation of payment and regulatory issues for the Medicare Advantage and Medicare Part D prescription drug programs, and of various CMS demonstration programs and of P.L. 111-148 (Patient Protection and Affordable Care Act). H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013.
Improve prescription drug access: H.R. 460: Patients Access to Treatments Act of 2013, S867. Medicare Prescription Drug Program Integrity and Transparency Act of 2013; provisions related to improving prescription drug access. Issues related to the high cost of specialty drugs; H.R. 4577 about pharmacy access and quality
Issues related to employer financing of private disability insurance.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Issues related to employer financing of private disability insurance.
Issues relating to general health and health care legislation and regulation - Including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010); H.R. 763 and S. 603, Jobs and Premium Protection Act, and medicare supplemental insurance. In addition, in support of H.R. 4414, The Expatriate Health Coverage Clarification Act.
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act) and H.R. 763; To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act and S. 603; Jobs and Premium Protection Act. In addition, H.R. 4414, The Expatriate Health Coverage Clarification Act, H.R 3367, The Small Business and Family Relief Act, and H.R. 3462 and S. 1735, about Self Insurance. Issues related to the new Taiwan financial services tax and its impact on foreign insurers.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Issues related to corporate taxation; taxation of health benefits and providers of health coverage, including P.L. 111-148 (Patient Protection and Affordable Care Act) and H.R. 763: To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act and S. 603: Jobs and Premium Protection Act. In addition, H.R. 4414, The Expatriate Health Coverage Clarification Act, H.R 3367, The Small Business and Family Relief Act, and H.R. 3462 and S 1735, about Self InsuranceIssues related to the new Taiwan financial services tax and its impact on foreign insurers.
Improve prescription drug access: H.R. 460: Patients Access to Treatments Act of 2013, S867. Medicare Prescription Drug Program Integrity and Transparency Act of 2013; provisions related to improving prescription drug access. Issues related to the high cost of specialty drugs.
Issues relating to general health and health care legislation and regulation - Including P.L. 111-148 (Patient Protection and Affordable Care Act) and P.L. 111-152 (Reconciliation Act of 2010); H.R. 763 and S. 603, Jobs and Premium Protection Act, and medicare supplemental insurance. In addition, in support of H.R. 4414, The Expatriate Health Coverage Clarification Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of, Vice President of the U.S.